Quarterly report pursuant to Section 13 or 15(d)

Licensing and Collaborative Agreements (Details Textuals)

v2.4.0.8
Licensing and Collaborative Agreements (Details Textuals) (USD $)
3 Months Ended 6 Months Ended 181 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 24 Months Ended 1 Months Ended 3 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2013
UHN [Member]
Sep. 30, 2012
UHN [Member]
Jun. 30, 2012
US NIH [Member]
Mar. 31, 2010
US NIH [Member]
Mar. 31, 2008
US NIH [Member]
Oct. 31, 2012
Cato [Member]
Jun. 30, 2013
Cato [Member]
Jun. 30, 2012
Cato [Member]
Monthly research funding payments             $ 50,000            
Promissory note issuance           549,500         1,009,000    
Warrant issued with promissory note                     1,009,000    
Research funding payments           309,000              
Award upon agreed milestones           3,900,000              
Grant revenue               187,000 4,600,000 4,200,000      
Research and development expenses $ 669,300 $ 1,106,300 $ 1,364,800 $ 1,972,600 $ 30,920,500             $ 30,000 $ 222,600